Received Oct 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
Confirmed no symptoms reported and no additional details provided; first dose in 2023/The next dose was not received per the dosing schedule in the Prescribing Information until 09/28/2925; This spontaneous report was received from a consumer or other non-health professional and refers to a female patient of unknown age. The patient's medical history, concurrent conditions, concomitant therapies, previous drugs reactions and allergies were not reported. On an unknown date in 2023, the patient was vaccinated with the first dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) 1 dosage form, administered as prophylaxis (Lot No., expiration date, strength, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided). On 28-Sep-2025, the patient was vaccinated with the second dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) 1 dosage form, administered as prophylaxis (Lot No., expiration date, strength, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided) (inappropriate schedule of product administration). Additionally, it was stated that the patient had not yet received the third dose of the previous mention vaccine. No other adverse event was reported (no adverse event).